Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bliss GVS Pharma OCF Yield % Related Terms
Bliss GVS Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bliss GVS Pharma (BOM:506197) has a OCF Yield % of 2.71 as of Jul. 18, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bliss GVS Pharma and its competitors. Over the past decade, Bliss GVS Pharma's OCF Yield % has ranged from 2.71 to 2.71. According to the industry distribution chart, Bliss GVS Pharma ranks #568 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 56.4%.
Is Bliss GVS Pharma's OCF Yield % too high?
Bliss GVS Pharma's current OCF Yield % is 2.71. Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 2.71. The Drug Manufacturers industry median OCF Yield % is 3.55. Bliss GVS Pharma's value of 2.71 is 23.7% below this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #568 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bliss GVS Pharma has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #568 out of 1007 companies for OCF Yield %. This places Bliss GVS Pharma in the lower half of its industry. The industry median OCF Yield % is 3.55. Bliss GVS Pharma's value of 2.71 is 23.7% below this benchmark. Historically, Bliss GVS Pharma's own OCF Yield % has ranged from 2.71 to 2.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.55, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current OCF Yield % of 2.71 is 23.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current OCF Yield % is 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹151.86, compared to a current price of ₹482.50 — trading 217.7% above its estimated fair value. The current OCF Yield % is 2.71 and 23.7% below the Drug Manufacturers industry median of 3.55. Bliss GVS Pharma's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current OCF Yield % is 2.71 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹482.50 is trading 217.7% above its estimated GF Value™ of ₹151.86.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
OCF Yield %: 2.71
GF Value™: ₹151.86 vs. price of ₹482.50 (217.7% above fair value)
Industry Position: 23.7% below the Drug Manufacturers median (#568 of 1007)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
57GF Score
Get the complete analysis for BOM:506197
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
